OR WAIT null SECS
There are considerations companies may want to consider before seeking out a service provider.
Strategizing a PK/PD study approach in early phase development facilitates a successful clinical progression.
Demand for efficient tech transfer, as well as compliant on-time delivery, is rising.
February 27, 2024
CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen.
February 05, 2024
The CDMOs are joining together to offer end-to-end development and manufacturing services for protein expression systems and viral vectors in Europe.
February 02, 2024
Under a new collaboration, Lonza and Oxford Nanopore aim to commercialize a CGMP-validated test for advanced analysis of mRNA products.
February 01, 2024
January 24, 2024
Under a new alliance, KBI Biopharma and Argonaut Manufacturing Services will combine their strengths to offer end-to-end biopharma development and CGMP manufacturing solutions.
January 18, 2024
The acquisition will give Novartis full rights to CALY-002, Calypso’s lead product candidate.
January 17, 2024
Charles River’s off-the-shelf rep/cap plasmids are intended to simplify gene therapy supply chains.
December 27, 2023
Andelyn Biosciences has been selected by Ultragenyx to manufacture UX111, that company’s gene therapy for treating Sanfilippo Syndrome.
December 20, 2023
Following the divestiture of its Elusys subsidiary and other non-core assets, NightHawk Biosciences will transform into a pure-play large-molecule CDMO.
December 14, 2023
RoslinCT will manufacture Vertex Pharmaceuticals’ CRISPR-based gene therapy, Casgevy, recently approved for treating sickle cell disease and β thalassemia.